EUVIMEDEUVIMED entdecken
Crossref

Evaluation of mechlorethamine, vinblastine, procarbazine, and prednisone for the treatment of resistant multicentric canine lymphoma

Kelley Zimmerman, Koranda A Walsh, Jonathan T Ferrari, Nicholas S Keuler, Matthew J Atherton iD, Jennifer A Lenz iD

Veterinary and Comparative Oncology · 2023

DOI: 10.1111/vco.12913 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Veterinary and Comparative Oncology, 2023. Verfasst von Kelley Zimmerman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Science & Advanced Medicine, University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Neoplasm Recurrence, Local, Dog Diseases, Lymphoma, Lymphoma, Non-Hodgkin. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multi‐agent chemotherapy successfully induces remission in most naïve, high‐grade canine lymphoma patients; however, disease recurrence is common. MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) is an effective rescue protocol used to re‐induce remission, but is associated with gastrointestinal toxicity and can be a less desirable option for patients that previously failed vincristine‐containing protocols. Therefore, alternative members of the vinca alkaloid family, such as vinblastine, could be potentially advantageous as substitutes for vincristine to reduce gastrointestinal toxicity and chemoresistance. The objective of this study was to report the clinical outcomes and toxicity of 36 dogs with relapsed or refractory multicentric lymphoma treated with a modified MOPP protocol whereby vincristine was replaced with vinblastine (MVPP). The overall response rate to MVPP was 25% with a median progression free survival of 15 days and a median overall survival of 45 days. MVPP at the prescribed doses resulted in modest and transient clinical benefit, but was well tolerated with no treatment delays or hospitalizations secondary to side effects. Given the minimal toxicity, dose intensification could be considered to improve clinical responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm Recurrence, LocalDog DiseasesLymphomaLymphoma, Non-HodgkinAnimalsDogsPrednisoneVinblastineMechlorethamineVincristineProcarbazineAntineoplastic Combined Chemotherapy ProtocolsDoxorubicin

Stichwörter der Autor:innen

chemotherapydogrescue

Substanzen

PrednisoneVinblastineMechlorethamineVincristineProcarbazineDoxorubicin

Autor:innen und Institutionen

  • Department of Clinical Science & Advanced Medicine, University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania, USA.
  • Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania, USA.
  • Surgical Oncology, The Schwarzman Animal Medical Center, New York, New York, USA.
  • Department of Statistics, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Department of Biomedical Sciences, University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Matthew J Atherton, Jennifer A Lenz

Zitieren

APA

Zimmerman, K., Walsh, K. A., Ferrari, J. T., Keuler, N. S., Atherton, M. J., & Lenz, J. A. (2023). Evaluation of mechlorethamine, vinblastine, procarbazine, and prednisone for the treatment of resistant multicentric canine lymphoma. Veterinary and Comparative Oncology. https://doi.org/10.1111/vco.12913

Vancouver

Zimmerman K, Walsh KA, Ferrari JT, Keuler NS, Atherton MJ, Lenz JA. Evaluation of mechlorethamine, vinblastine, procarbazine, and prednisone for the treatment of resistant multicentric canine lymphoma. Veterinary and Comparative Oncology. 2023. doi:10.1111/vco.12913

BibTeX
@article{Zimmerman2023,
  author = {Zimmerman, Kelley and Walsh, Koranda A and Ferrari, Jonathan T and Keuler, Nicholas S and Atherton, Matthew J and Lenz, Jennifer A},
  title = {Evaluation of mechlorethamine, vinblastine, procarbazine, and prednisone for the treatment of resistant multicentric canine lymphoma},
  journal = {Veterinary and Comparative Oncology},
  year = {2023},
  doi = {10.1111/vco.12913}
}
Kostenlos starten →